United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $929,124.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total transaction of $929,124.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $33,551.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Trading Up 1.7 %

Shares of NASDAQ UTHR opened at $262.40 on Friday. United Therapeutics Co. has a twelve month low of $204.44 and a twelve month high of $262.51. The stock has a market cap of $11.64 billion, a price-to-earnings ratio of 12.41 and a beta of 0.54. The company has a quick ratio of 4.28, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average is $236.86 and its 200-day moving average is $229.40.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company’s revenue was up 33.7% on a year-over-year basis. During the same period in the previous year, the firm earned $4.86 earnings per share. Equities research analysts predict that United Therapeutics Co. will post 23.75 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent research reports. Oppenheimer boosted their target price on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday. HC Wainwright restated a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a research report on Thursday. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Finally, SVB Leerink began coverage on shares of United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 target price for the company. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $308.78.

Institutional Trading of United Therapeutics

Large investors have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale boosted its holdings in shares of United Therapeutics by 54.4% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock valued at $20,617,000 after buying an additional 33,338 shares during the period. Nordea Investment Management AB increased its holdings in United Therapeutics by 155.2% during the 4th quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock worth $8,427,000 after purchasing an additional 23,532 shares in the last quarter. Duality Advisers LP raised its stake in shares of United Therapeutics by 56.1% in the 4th quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock valued at $3,440,000 after purchasing an additional 5,622 shares during the period. Louisiana State Employees Retirement System bought a new stake in shares of United Therapeutics in the fourth quarter valued at about $2,903,000. Finally, O Shaughnessy Asset Management LLC lifted its holdings in shares of United Therapeutics by 4.9% in the third quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company’s stock valued at $520,000 after purchasing an additional 107 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.